![ASCO 2022 Conference Coverage](http://media.vumedi.com/thumbs/channel_logo/2022/5/eadfa937-de35-4504-be38-58654669525f.png.200x0_q85.png)
ASCO 2022 Conference Coverage
Lecture Summary - ASCO 2022 Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in HER2+ Unresectable and/or Metastatic Breast Cancer: Safety Follow-Up of the Phase 3 DESTINY-Breast03
By
ASCO 2022 Conference Coverage
FEATURING
Erika Hamilton
By
ASCO 2022 Conference Coverage
FEATURING
Erika Hamilton
416 views
June 13, 2022
Comments 0
Login to view comments.
Click here to Login
Breast